Forward-Looking Statements
This press release contains forward-looking statements based on Silicon Labs' current expectations. The words "believe," "estimate," "expect," "intend," "anticipate," "plan," "project," "will" and similar phrases as they relate to Silicon Labs are intended to identify such forward-looking statements. These forward-looking statements reflect the current views and assumptions of Silicon Labs and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. Among the factors that could cause actual results to differ materially from those in the forward-looking statements are the following: the impact of COVID-19 on the U.S. and global economy, including the restrictions on travel and transportation and other actions that may be taken by governmental authorities and disruptions to the business of our customers or our global supply chain, the impact of COVID-19 on our employees and our ability to provide services to our customers and respond to their needs; risks that Silicon Labs may not be able to maintain its historical growth; quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with international activities (including trade barriers); intellectual property litigation risks; risks associated with acquisitions and divestitures; product liability risks; difficulties managing Silicon Labs' distributors, manufacturers and subcontractors; dependence on a limited number of products; absence of long-term commitments from customers; inventory-related risks; difficulties managing international activities; risks that Silicon Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; dependence on key personnel; stock price volatility; geographic concentration of manufacturers, assemblers, test service providers and customers in Asia that subjects Silicon Labs' business and results of operations to risks of natural disasters, epidemics or pandemics, war and political unrest; debt-related risks; capital-raising risks; the competitive and cyclical nature of the semiconductor industry; average selling prices of products may decrease significantly and rapidly; information technology risks; cyber-attacks against Silicon Labs' products and its networks; conflict mineral risks and other factors that are detailed in the SEC filings of Silicon Laboratories Inc. Silicon Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. References in this press release to Silicon Labs shall mean Silicon Laboratories Inc.
Note to editors: Silicon Laboratories, Silicon Labs, the "S" symbol, and the Silicon Labs logo are trademarks of Silicon Laboratories Inc. All other product names noted herein may be trademarks of their respective holders.
CONTACT: Jalene Hoover, +1 (512) 428-1610, Jalene.Hoover@silabs.com
Silicon Laboratories Inc. | |||
Condensed Consolidated Statements of Income | |||
(In thousands, except per share data) | |||
(Unaudited) | |||
| |||
| Three Months Ended | ||
| April 4,
|
| March 30,
|
Revenues | $214,877 |
| $188,113 |
Cost of revenues | 85,711 |
| 72,239 |
Gross profit | 129,166 |
| 115,874 |
Operating expenses: |
|
|
|
Research and development | 71,223 |
| 61,566 |
Selling, general and administrative | 53,996 |
| 49,216 |
Operating expenses | 125,219 |
| 110,782 |
Operating income | 3,947 |
| 5,092 |
Other income (expense): |
|
|
|
Interest income and other, net | 3,251 |
| 2,823 |
Interest expense | (5,541) |
| (4,997) |
Income before income taxes | 1,657 |
| 2,918 |
Provision (benefit) for income taxes | (587) |
| (2,480) |
Net income | $ 2,244 |
| $ 5,398 |
|
|
|
|
Earnings per share: |
|
|
|
Basic | $ 0.05 |
| $ 0.12 |
Diluted | $ 0.05 |
| $ 0.12 |
|
|
|
|
Weighted-average common shares outstanding: |
|
|
|
Basic | 43,642 |
| 43,189 |
Diluted | 44,388 |
| 43,716 |
Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures | ||||||||||||||||
(In thousands, except per share data) | ||||||||||||||||
| ||||||||||||||||
Non-GAAP Income
|
| Three Months Ended April 4, 2020 | ||||||||||||||
|
| GAAP Measure |
| GAAP Percent of
|
| Stock Compensation
|
| Intangible
|
| Acquisition
|
| Restructuring
|
| Non-GAAP Measure |
| Non-GAAP Percent of
|
Revenues |
| $214,877 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin |
| 129,166 |
| 60.1% |
| $ 335 |
| $ -- |
| $ 151 |
| $ 45 |
| $129,697 |
| 60.4% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
| 71,223 |
| 33.1% |
| 7,370 |
| 7,167 |
| -- |
| 1,434 |
| 55,252 |
| 25.7% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative |
| 53,996 |
| 25.2% |
| 7,608 |
| 2,505 |
| 1,284 |
| 1,318 |
| 41,281 |
| 19.3% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
| 3,947 |
| 1.8% |
| 15,313 |
| 9,672 |
| 1,435 |
| 2,797 |
| 33,164 |
| 15.4% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP
|
| Three Months Ended April 4, 2020 | ||||||||||||||
|
| GAAP Measure |
| Stock Compensation
|
| Intangible
|
| Acquisition
|
| Restructuring
|
| Non-cash
|
| Income Tax Adjustments |
| Non-
|
Net income |
| $ 2,244 |
| $15,313 |
| $9,672 |
| $1,435 |
| $2,797 |
| $3,246 |
| $(4,001) |
| $30,706 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted shares outstanding |
| 44,388 |
|
|
|
|
|
|
|
|
|
|
|
|
| 44,388 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share |
| $ 0.05 |
|
|
|
|
|
|
|
|
|
|
|
|
| $ 0.69 |
|
* Represents pre-tax amounts |
Unaudited Forward-Looking Statements Regarding Business Outlook | ||||||
(In millions, except per share data) | ||||||
| ||||||
Business Outlook |
| Three Months Ending July 4, 2020 | ||||
|
| GAAP Measure |
| Non-GAAP Adjustments* |
| Non-GAAP Measure |
Gross margin |
| 60.5% |
| 0.5% |
| 61.0% |
|
|
|
|
|
|
|
Operating expenses |
| $122.0 |
| $29.5 |
| $92.5 |
|
|
|
|
|
|
|
Effective tax rate |
| 0.0% |
| 10.5% |
| 10.5% |
|
|
|
|
|
|
|
Diluted earnings (loss) per share - low |
| $(0.26) |
| $0.71 |
| $0.45 |
|
|
|
|
|
|
|
Diluted earnings per share - high |
| $(0.03) |
| $0.71 |
| $0.68 |
|
* Non-GAAP adjustments include the following estimates: stock compensation expense of $13.7 million, intangible asset amortization of $13.0 million, acquisition related items of $2.9 million, restructuring charges of $1.2 million, and non-cash interest expense of $3.0 million, and associated tax impact from the aforementioned items. |
Silicon Laboratories Inc. | |||
Condensed Consolidated Balance Sheets | |||
(In thousands, except per share data) | |||
(Unaudited) | |||
| |||
| April 4,
|
| December 28,
|
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents | $ 615,770 |
| $ 227,146 |
Short-term investments | 442,493 |
| 498,825 |
Accounts receivable, net | 74,620 |
| 75,639 |
Inventories | 68,160 |
| 73,057 |
Prepaid expenses and other current assets | 46,994 |
| 69,192 |
Total current assets | 1,248,037 |
| 943,859 |
Property and equipment, net | 136,391 |
| 135,939 |
Goodwill | 398,402 |
| 398,402 |
Other intangible assets, net | 124,604 |
| 134,279 |
Other assets, net | 63,648 |
| 62,374 |
Total assets | $1,971,082 |
| $1,674,853 |
|
|
|
|
Liabilities and Stockholders' Equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable | $ 42,147 |
| $ 38,899 |
Revolving line of credit | 310,000 |
| -- |
Deferred revenue and returns liability | 23,365 |
| 19,251 |
Other current liabilities | 71,221 |
| 79,551 |
Total current liabilities | 446,733 |
| 137,701 |
Convertible debt | 371,993 |
| 368,257 |
Other non-current liabilities | 52,753 |
| 53,844 |
Total liabilities | 871,479 |
| 559,802 |
Commitments and contingencies |
|
|
|
Stockholders' equity: |
|
|
|
Preferred stock – $0.0001 par value; 10,000 shares authorized; no shares issued | -- |
| -- |
Common stock – $0.0001 par value; 250,000 shares authorized; 43,670 and 43,496 shares issued and outstanding at April 4, 2020 and December 28, 2019, respectively | 4 |
| 4 |
Additional paid-in capital | 116,553 |
| 133,793 |
Retained earnings | 983,377 |
| 980,608 |
Accumulated other comprehensive income (loss) | (331) |
| 646 |
Total stockholders' equity | 1,099,603 |
| 1,115,051 |
Total liabilities and stockholders' equity | $1,971,082 |
| $1,674,853 |
Silicon Laboratories Inc. | ||||
Condensed Consolidated Statements of Cash Flows | ||||
(In thousands) | ||||
(Unaudited) | ||||
| ||||
| Three Months Ended |
| ||
| April 4,
|
| March 30,
|
|
Operating Activities |
|
|
|
|
Net income | $ 2,244 |
| $ 5,398 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
Depreciation of property and equipment | 4,183 |
| 4,137 |
|
Amortization of other intangible assets and other assets | 9,827 |
| 10,320 |
|
Amortization of debt discount and debt issuance costs | 3,736 |
| 3,321 |
|
Stock-based compensation expense | 15,313 |
| 12,584 |
|
Deferred income taxes | (2,364) |
| (3,530) |
|
Changes in operating assets and liabilities: |
|
|
|
|
Accounts receivable | 1,542 |
| 3,323 |
|
Inventories | 4,777 |
| 4,488 |
|
Prepaid expenses and other assets | 23,576 |
| 6,410 |
|
Accounts payable | 2,748 |
| 714 |
|
Other current liabilities and income taxes | (9,134) |
| (15,996) |
|
Deferred revenue and returns liability | 4,114 |
| 1,477 |
|
Other non-current liabilities | (862) |
| (631) |
|
Net cash provided by operating activities | 59,700 |
| 32,015 |
|
|
|
|
|
|
Investing Activities |
|
|
|
|
Purchases of available-for-sale investments | (70,910) |
| (63,577) |
|
Sales and maturities of available-for-sale investments | 126,920 |
| 99,068 |
|
Purchases of property and equipment | (4,135) |
| (3,874) |
|
Purchases of other assets | (370) |
| (414) |
|
Net cash provided by investing activities | 51,505 |
| 31,203 |
|
|
|
|
|
|
Financing Activities |
|
|
|
|
Proceeds from revolving line of credit | 310,000 |
| -- |
|
Repurchases of common stock | (16,287) |
| (15,004) |
|
Payment of taxes withheld for vested stock awards | (16,294) |
| (14,113) |
|
Net cash provided by (used in) financing activities | 277,419 |
| (29,117) |
|
|
|
|
|
|
Increase in cash and cash equivalents | 388,624 |
| 34,101 |
|
Cash and cash equivalents at beginning of period | 227,146 |
| 197,043 |
|
Cash and cash equivalents at end of period | $615,770 |
| $231,144 |
|
View original content to download multimedia: http://www.prnewswire.com/news-releases/silicon-labs-announces-first-quarter-2020-results-301048904.html
SOURCE Silicon Labs
Contact: |
Company Name: Silicon Labs
Web: http://www.silabs.com Financial data for Silicon Labs |